David Young

Who is David Young?

Dr. Young is currently President of AGI Therapeutics, Inc. Previously, Dr. Young was the Executive

Vice President of the Strategic Drug Development Division of ICON plc, an international CRO, and founder

and CEO of GloboMax LLC, a contract drug development firm purchased by ICON plc in 2003. Prior to

forming GloboMax, Dr. Young was an Associate Professor at the School of Pharmacy, University of Maryland

where he held a number of roles including Director of the Pharmacokinetics and Biopharmaceutics Lab and

Managing Director of the University of Maryland-VA Clinical Research Unit. Dr. Young has represented

more than 30 sponsors at the Food and Drug Administration (FDA), worked on more than 70 drug products,

and been involved with more than 30 NDA submissions. Dr. Young has an extensive background in drug

development that includes more than 150 presentations and authored publications, including formal

presentations to the FDA and numerous invited presentations at scientific meetings. Dr. Young is

an expert in 505(b)(2) drug development, having worked on more than 25 programs in various therapeutic

areas including Central Nervous System (CNS) diseases and disorders.